India Court Rejects Cancer Drug Patent Bid - Presented by: The Aol. On Network

Residents in India's capital New Delhi form long queues at this pharmacy. The country is home to a drugs market that grows between 13 and 14 percent every year, making it an attractive investment for Western pharmaceutical companies. But a landmark court ruling could change that. On Monday, India's top court rejected a bid by Swiss drug-maker Novartis to win patent protection for its cancer drug, Glivec.



Related Videos

Most Popular Videos

Latest Videos


Most Active by Volume

Company Last Sale Change Net / %
AAPL $ 100.86 0.77 ▼ 0.76%
BAC $ 16.71 0.03 ▼ 0.18%
YHOO $ 42.71 0.16 ▲ 0.38%
PBR $ 17.51 0.97 ▲ 5.86%
GRT $ 13.75 3.16 ▲ 29.84%
AA $ 16.16 0.23 ▼ 1.40%
SIRI $ 3.605 0.02 ▲ 0.56%
AMD $ 3.81 0.10 ▼ 2.56%

As of 9/16/2014, 04:15 PM
More Most Active